Monsanto Company

Thomas G Warren

Tze-Chein Wun

Leslie D Bell

H Eser Tolunay

Mark O Palmier

Ernest J Mayer

A modified t-PA having improved in vivo half-life is disclosed comprising in sequence a fibronectin finger-like domain F, a growth factor domain GF, a sequence of two K2 kringle regions and a serine protease region SP, wherein the first of said kringles is free of any glycosylation site and the second of said kringles has a single glycosylation site.

Modified tissue plasminogen activator with modified glycosylation site

A modified t-PA having improved in vivo half-life is disclosed comprising in sequence a sequence of two K2 kringle regions and a serine protease region SP.

Modified tissue plasminogen activator K2K2SP

A modified tissue plasminogen activator having an improved in vivo half-life characterized in that the normal protein moiety of 527 amino acids is mutated at the site Cys73.fwdarw.Arg and at the site Lys277.fwdarw.Asp.

Modified tissue plasminogen activator substituted at cysteine-73 and

A modified tissue plasminogen activator having an improved in vivo half-life characterized in that the normal protein moiety of 527 amino acids is mutated at the site Cys73.fwdarw.Arg.

Growing community of inventors

Ballwin, MO, United States of America

Thomas G Warren